Douglas Hanahan

Q: What Schools Are Affiliated With Douglas Hanahan

Douglas Hanahan is affiliated with the following schools: University of Oxford, Central South University, École Polytechnique Fédérale de Lausanne, Massachusetts Institute of Technology, Baylor College of Medicine, University of Toronto, University of California, San Francisco, Massachusetts General Hospital, Harvard University

Douglas Hanahan's AcademicInfluence.com Rankings

Douglas Hanahan

Biology

#645

World Rank

#1133

Historical Rank

#359

USA Rank

Cell Biology

#18

World Rank

#20

Historical Rank

#10

USA Rank

biology Degrees

Download Badge

Biology

Why Is Douglas Hanahan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Douglas Hanahan is an American biologist, professor and director emeritus of the Swiss Institute for Experimental Cancer Research at EPFL in Lausanne, Switzerland. He is currently member of the Lausanne branch of the Ludwig Institute.

(See a Problem?)

Douglas Hanahan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hallmarks of Cancer: The Next Generation (2011) (45671)
The Hallmarks of Cancer (2000) (29017)
Studies on transformation of Escherichia coli with plasmids. (1983) (10727)
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis (1996) (7081)
Accessories to the crime: functions of cells recruited to the tumor microenvironment. (2012) (3496)
The Consensus Molecular Subtypes of Colorectal Cancer (2015) (3194)
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (2000) (2727)
Modes of resistance to anti-angiogenic therapy (2008) (2716)
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. (2009) (2366)
Induction of angiogenesis during the transition from hyperplasia to neoplasia (1989) (1959)
MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes (1998) (1786)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. (2005) (1584)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. (2003) (1398)
MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis (2000) (1345)
Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy (2011) (1299)
Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes (1985) (1298)
Signaling Vascular Morphogenesis and Maintenance (1997) (1247)
Hallmarks of Cancer: New Dimensions. (2022) (1233)
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. (2010) (1222)
Differential plasmid rescue from transgenic mouse DNAs into Escherichia coli methylation-restriction mutants. (1990) (1198)
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. (1999) (994)
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. (1999) (980)
Tissue-penetrating delivery of compounds and nanoparticles into tumors. (2009) (953)
A colorectal cancer classification system that associates cellular phenotype and responses to therapy (2013) (854)
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis (2006) (818)
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. (2000) (791)
Plasmid screening at high colony density. (1980) (727)
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. (2004) (647)
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. (2006) (632)
Plasmid transformation of Escherichia coli and other bacteria. (1991) (607)
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. (2004) (576)
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. (2006) (567)
Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma (1991) (534)
Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. (1988) (520)
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. (2006) (506)
Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction (1997) (500)
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. (2005) (487)
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation (2017) (473)
BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. (2000) (469)
Hybrid insulin genes reveal a developmental lineage for pancreatic endocrine cells and imply a relationship with neurons (1988) (452)
Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting (2008) (420)
A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis (1994) (419)
Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. (1998) (415)
Betacellulin: a mitogen from pancreatic beta cell tumors. (1993) (410)
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. (2002) (398)
GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. (2009) (390)
Genetic and physical linkage of exogenous sequences in transformed cells (1980) (386)
Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. (1993) (376)
Transgenic mice as probes into complex systems. (1989) (370)
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. (1996) (362)
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. (2016) (353)
Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy (1997) (348)
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. (2002) (333)
McrA and McrB restriction phenotypes of some E. coli strains and implications for gene cloning. (1988) (324)
Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. (1997) (320)
Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. (1996) (315)
Lineage-specific morphogenesis in the developing pancreas: role of mesenchymal factors. (1996) (311)
Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice (1994) (310)
Cellular transformation and malignancy induced by ras require c-jun (1996) (304)
Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis (1996) (295)
Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. (1999) (288)
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. (2002) (287)
Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells (1987) (278)
Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. (2011) (274)
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. (2009) (273)
Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. (2013) (260)
Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. (1999) (251)
Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas (2001) (248)
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. (2003) (248)
Bioavailable copper modulates oxidative phosphorylation and growth of tumors (2013) (239)
T-cell tolerance toward a transgenic beta-cell antigen and transcription of endogenous pancreatic genes in thymus. (1994) (237)
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy (2010) (235)
Synaptic proximity enables NMDAR signaling to promote brain metastasis (2019) (233)
Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. (1996) (231)
Of Mice and MEN1: Insulinomas in a Conditional Mouse Knockout (2003) (229)
Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. (2010) (229)
Switch to the angiogenic phenotype during tumorigenesis. (1991) (227)
Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. (1996) (226)
The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. (1996) (221)
Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. (2003) (220)
Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. (1995) (217)
Dissecting multistep tumorigenesis in transgenic mice. (1988) (212)
Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. (1997) (209)
Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. (1997) (204)
Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. (2008) (203)
Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity. (1998) (192)
Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells (2003) (191)
[24] Plasmid screening at high colony density (1983) (184)
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma (2017) (172)
Multiple Roles for Cysteine Cathepsins in Cancer (2004) (169)
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling (2016) (167)
Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic a cells (1988) (164)
The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. (2007) (164)
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. (2011) (163)
Isolation of the chicken thymidine kinase gene by plasmid rescue (1980) (160)
Endogenous Myc maintains the tumor microenvironment. (2011) (160)
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer (2005) (159)
Directed expression of NGF to pancreatic β cells in transgenic mice leads to selective hyperinnervation of the islets (1989) (159)
Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. (2018) (159)
Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. (1995) (158)
Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit. (2015) (150)
The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities (2012) (143)
Endothelial cell tumors develop in transgenic mice carrying polyoma virus middle T oncogene (1987) (141)
Proglucagon Processing Similar to Normal Islets in Pancreatic α-Like Cell Line Derived From Transgenic Mouse Tumor (1990) (139)
Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. (1998) (139)
Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen. (1995) (138)
Infection of eucaryotic cells by helper-independent recombinant adenoviruses: early region 1 is not obligatory for integration of viral DNA (1984) (136)
Roadmap for the Emerging Field of Cancer Neuroscience (2020) (136)
Characteristics of an SV40-plasmid recombinant and its movement into and out of the genome of a murine cell (1980) (135)
Rethinking the war on cancer (2014) (129)
A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. (2015) (129)
Deregulation of both imprinted and expressed alleles of the insulin–like growth factor 2 gene during β–cell tumorigenesis (1995) (128)
Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition (2011) (128)
Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. (1997) (123)
Bovine papillomavirus genome elicits skin tumours in transgenic mice (1986) (121)
Hijacking the Neuronal NMDAR Signaling Circuit to Promote Tumor Growth and Invasion (2013) (120)
Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. (2007) (110)
Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. (1996) (109)
Overexpression of Bcl-x(L) in beta-cells prevents cell death but impairs mitochondrial signal for insulin secretion. (2000) (108)
Proliferation, senescence, and neoplastic progression of β cells in hyperplasic pancreatic islets (1988) (102)
Pancreatic beta cells cultured from individual preneoplastic foci in a multistage tumorigenesis pathway: a potentially general technique for isolating physiologically representative cell lines (1993) (102)
Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. (2010) (101)
Direct Test of Potential Roles of EIIIA and EIIIB Alternatively Spliced Segments of Fibronectin in Physiological and Tumor Angiogenesis (2004) (98)
Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. (1998) (95)
CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. (2005) (91)
Translational medicine: Cancer lessons from mice to humans (2011) (84)
Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer (2002) (81)
Increased expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. (2000) (81)
Structure of the pro α2(I) collagen gene (1981) (80)
Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. (1995) (79)
Reconciliation of classification systems defining molecular subtypes of colorectal cancer (2014) (77)
Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. (1994) (77)
Neuroepithelial carcinomas in mice transgenic with human papillomavirus type 16 E6/E7 ORFs. (1993) (76)
Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. (1996) (73)
Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas (2001) (71)
Lymphatic zip codes in premalignant lesions and tumors. (2006) (71)
Assessing Tumor Progression Factors by Somatic Gene Transfer into a Mouse Model: Bcl-xL Promotes Islet Tumor Cell Invasion (2007) (71)
L-selectin can facilitate metastasis to lymph nodes in a transgenic mouse model of carcinogenesis (2001) (71)
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma (2011) (69)
Transcription factors junB and c-jun are selectively up-regulated and functionally implicated in fibrosarcoma development. (1992) (68)
A flanking attack on cancer (1998) (65)
Breaching the Cancer Fortress (2009) (62)
The Hallmarks of Cancer Review (2000) (62)
Construction and characterization of pro alpha 1 collagen complementary deoxyribonucleic acid clones. (1979) (62)
A Subset of Cancer-Associated Fibroblasts Determines Therapy Resistance (2018) (61)
Construction and characterization of a 2.5-kilobase procollagen clone. (1978) (60)
FISH probes for mouse chromosome identification. (1997) (59)
Molecular dissection of multi-stage tumorigenesis in transgenic mice. (1994) (59)
Genetic Deletion of the Desmosomal Component Desmoplakin Promotes Tumor Microinvasion in a Mouse Model of Pancreatic Neuroendocrine Carcinogenesis (2010) (57)
Murine pancreatic ductal adenocarcinoma produced by in vitro transduction of polyoma middle T oncogene into the islets of Langerhans. (1994) (57)
Diabetes induced in male transgenic mice by expression of human H-ras oncoprotein in pancreatic beta cells (1990) (54)
Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner (2011) (54)
Molecular cloning of mouse pancreatic islet R-cadherin: differential expression in endocrine and exocrine tissue. (1993) (52)
Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. (2011) (52)
A biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice. (2013) (50)
Early invasiveness characterizes metastatic carcinoid tumors in transgenic mice. (1991) (49)
cDNA sequence of neuroendocrine protein 7B2 expressed in beta cell tumors of transgenic mice. (2009) (49)
Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis (2013) (48)
Mouse models for the study of telomerase. (1997) (44)
Tumor Cells Utilize Multiple Pathways to Down‐modulate Apoptosis: Lessons from a Mouse Model of Islet Cell Carcinogenesis (1999) (43)
Dendritic Cells in Human Thymus and Periphery Display a Proinsulin Epitope in a Transcription-Dependent, Capture-Independent Fashion 1 (2005) (43)
GKAP Acts as a Genetic Modulator of NMDAR Signaling to Govern Invasive Tumor Growth (2018) (42)
Rescue of functional replication origins from embedded configurations in a plasmid carrying the adenovirus genome (1984) (40)
Transgenic mouse models of self-tolerance and autoreactivity by the immune system. (1990) (38)
Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. (2013) (38)
A transition in transcriptional activation by the glucocorticoid and retinoic acid receptors at the tumor stage of dermal fibrosarcoma development. (1995) (38)
Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors. (2003) (38)
Bidirectional activity of the rat insulin II 5'-flanking region in transgenic mice (1987) (37)
Cell-heritable stages of tumor progression in transgenic mice harboring the bovine papillomavirus type 1 genome (1989) (36)
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy (2013) (36)
A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy. (2013) (35)
Glucose transporter isotypes switch in T-antigen-transformed pancreatic beta cells growing in culture and in mice (1992) (35)
A set of microRNAs coordinately controls tumorigenesis, invasion, and metastasis (2019) (34)
The metabolic pattern of C14-diethylstilbestrol. (1953) (34)
Differential Contribution to Neuroendocrine Tumorigenesis of Parallel Egfr Signaling in Cancer Cells and Pericytes (2010) (33)
Specific chromosomal abnormalities characterize fibrosarcomas of bovine papillomavirus type 1 transgenic mice. (1989) (33)
Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis (2005) (33)
Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. (2002) (31)
Oncogene Expression and Genetic Background Influence the Frequency of DNA Copy Number Abnormalities in Mouse Pancreatic Islet Cell Carcinomas (2004) (30)
Biological Hallmarks of Cancer (2017) (29)
Low temperature stopped-flow spectrometry. (1980) (27)
Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients (2018) (27)
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. (2004) (26)
Matrix metalloproteinase-9 triggers the angiogenic switch during (2000) (26)
Fibroblast growth factor receptor 4, implicated in progression of islet cell carcinogenesis by its expression profile, does not contribute functionally. (1998) (26)
Fine structural analysis of the chicken pro alpha 2 collagen gene. (1981) (26)
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells (2022) (25)
Determinants of the B-cell response against a transgenic autoantigen. (1990) (25)
Cancer: Benefits of bad telomeres (2000) (25)
Towards a cancer mission in Horizon Europe: recommendations (2020) (24)
ALK7 Signaling Manifests a Homeostatic Tissue Barrier That Is Abrogated during Tumorigenesis and Metastasis. (2019) (24)
Coordinate expression of the endogenous p53 gene in beta cells of transgenic mice expressing hybrid insulin‐SV40 T antigen genes. (1987) (23)
The hallmarks of cancer revisited (2012) (22)
Loss of p19Arf Facilitates the Angiogenic Switch and Tumor Initiation in a Multi-Stage Cancer Model via p53-Dependent and Independent Mechanisms (2010) (21)
Oncogenesis in Transgenic Mice (1986) (21)
Constitutively active stimulatory G-protein alpha s in beta-cells of transgenic mice causes counterregulation of the increased adenosine 3',5'-monophosphate and insulin secretion. (1994) (21)
DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice (1997) (21)
Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis (2010) (21)
Expression of human tissue-type plasminogen activator from lytic viral vectors and in established cell lines. (1986) (19)
Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice (2018) (19)
Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors (2019) (19)
Insulin-like growth factor II is focally up-regulated and functionally involved as a second signal for oncogene-induced tumorigenesis. (1994) (19)
Transgenic mouse model: a new approach for the investigation of endocrine pancreatic B-cell growth. (1987) (18)
Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes. (2004) (18)
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers (2019) (18)
Identification and Characterization of Poorly Differentiated Invasive Carcinomas in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis (2013) (16)
Alternative self or nonself recognition of an antigen expressed in a rare cell type in transgenic mice: implications for self-tolerance and autoimmunity. (1989) (16)
Genetic Ablation of Bcl-x Attenuates Invasiveness without Affecting Apoptosis or Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Cancer (2009) (16)
Directional cDNA cloning in plasmid vectors by sequential addition of oligonucleotide linkers. (1987) (15)
Transplantation of beta cells from transgenic mice into nude athymic diabetic rats restores glucose regulation. (1991) (14)
Deficiency for the Cysteine Protease Cathepsin L Impairs Myc-Induced Tumorigenesis in a Mouse Model of Pancreatic Neuroendocrine Cancer (2015) (14)
Judah Folkman (1933-2008) (2008) (13)
Cancer cells retrace a stepwise differentiation program during malignant progression. (2021) (12)
Cell factories for fighting cancer (2001) (12)
Chapter 2 : Hallmarks of Cancer : An Organizing Principle for Cancer Medicine (2015) (11)
Plasmid screening at high colony density. (1983) (11)
Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity (2022) (10)
The Hallmarks of Cancer Review evolve progressively from normalcy via a series of pre - (1999) (10)
Tumour development: Oncogenes in transgenic mice (1984) (10)
Procathepsin E is highly abundant but minimally active in pancreatic ductal adenocarcinoma tumors (2016) (9)
Evidence for threshold effects in transformation of pancreatic beta cells by SV40 T antigen in transgenic mice. (1989) (8)
Ultrastructure and electron immunocytochemistry of insulin-producing B-cell tumors from transgenic mice: comparison with counterpart human tumors. (1988) (8)
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages. (2023) (5)
Synaptic proximity enables NMDAR signalling to promote brain metastasis (2019) (5)
Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response (2014) (5)
Tissue specificity of oncogene action: endothelial cell tumours in polyoma middle T transgenic mice. (1989) (5)
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion (2022) (5)
Towards a Cancer Mission in Horizon Europe (2019) (5)
Diabetes Induced inMaleTransgenic MicebyExpression ofHuman H-rasOncoprotein inPancreatic Cells (1990) (4)
Time-resolved imaging system for fluorescence-guided surgery with lifetime imaging capability (2014) (4)
The Porto European Cancer Research Summit 2021 (2021) (4)
DNA Mediated Gene Transfer: Theory and Application (1980) (4)
Fine structural analysis of the chicken pro a2 collagen gene (4)
The cancer wars 2 Rethinking the war on cancer (2014) (3)
Tumorigenic latency and separable stages during fibrosarcoma development in transgenic mice carrying papillomavirus genomes. (1989) (3)
Perspectives on the molecular biology and immunology of the pancreatic β cell (1989) (3)
Gene Transfer : Transformation Mechanisms of DNA Transformation (1999) (3)
MECHANISMS OF DNA-MEDIATED TRANSFORMATION IN ANIMAL CELLS (1980) (3)
Structure of the pro alpha 2 (I) collagen gene. (1981) (3)
Oncogenes in transgenic mice. (1984) (3)
The cancer wars 2 Rethinking the war on cancer (2014) (3)
82: Hallmarks of cancer: applications to cancer medicine? (2014) (2)
Erratum: Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas (Journal of Vascular Technology (2001) 29 (459-464)) (2001) (2)
A general method for genotyping mast cell-deficient KITW/KITWυ mice by allele-specific polymerase chain reaction (1998) (2)
Basic and clinical research on angiogenesis (1996) (2)
Zoledronic acid inhibit angiogenesis and impairs tumorigenesis in a mouse model of cervical carcinogenesis (2009) (2)
Identification of Molecular Subtypes in Pancreatic Adenocarcinoma with Predictive and Prognostic Importance (2011) (2)
Abstract IA25: Hallmark capabilities modulated by the tumor microenvironment during tumor progression and adaptive resistance to therapy (2016) (1)
Phase 1 trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors (2008) (1)
Structure of lecithins, inositol phosphatides and acetal phosphatides. (1957) (1)
High-resolution assessment of DNA loss in RIP-Tag mouse pancreatic carcinomas using comparative genomic hybridization to microarrays (1999) (1)
A CCR4 antagonist combined with vaccines induces antigen-speciﬁc CD8 (cid:1) T cells and tumor immunity against self antigens (2011) (1)
Biologically Pure Escherichia-Coli Cell Line Which Is a Deo-R-Negative Mutant and Which Is More Transformation Efficient with Foreign Plasmids Than Deo-R-Positive Escherichia-Coli Cell Lines Processes for Obtaining These Cell Lines Methods of Use Us Patent-4851348. July 25 1989 (1989) (1)
A 11 Patent Number : 5 , 709 , 844 45 Date of Patent : Jan . 20 , 1998 Griep (2017) (0)
33 Hallmarks of cancer, ten years later: evolving principles, and therapeutic targeting (2010) (0)
Swiss Medical Weekly recognizes Prof Andrea Alimonti, recipient of the Dr Josef Steiner Cancer Research Foundation Award 2015. (2017) (0)
Unsorted single-cell RNA sequencing profiles of metastatic melanoma patients reveal the heterogeneity of melanoma-associated fibroblasts (2019) (0)
Expression of General Neuroendocrine Markers and Hormones in Pancreatic Glucagonomas of Transgenic Mice (1990) (0)
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer (2005) (0)
Abstract SY18-02: Molecular genetic subtypes of pancreas and colon cancer: Phenotypes and potential therapeutic significance. (2013) (0)
Metabolic Symbiosis Enab les Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent onmTOR Signaling Graphical (2016) (0)
Factors Modulating Immunological Non-Responsivenes and Autoimmunity in Insulin T Antigen Transgenic Mice (1989) (0)
Wanted: cancer boss (2006) (0)
Plasmid Rescue Using Escherichia-Coli Methylation-Restriction Mutants Allows Efficient Cloning of Transgenic Mouse DNA and Implicates DNA Modifications That Correlate with Developmental Timing of Transgene Expression (1990) (0)
Lab OHSU Center for Spatial Systems Biomedicine Platelet-Derived Soluble and Membrane-Bound Proteins Differentially Influence C-MYC Expression in Pancreatic Cancer Cells (2015) (0)
This information is current as Capture-Independent Fashion Transcription-Dependent, Periphery Display a Proinsulin Epitope in a Dendritic Cells in Human Thymus and (2013) (0)
Abstract 71: The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity (2021) (0)
A transition intranscriptional activation bythe glucocorticoid andretinoic acidreceptors atthe tumorstageofdermalfibrosarcoma development (1995) (0)
Genomics of islet cell carcinogenesis (2001) (0)
GKAP Acts as a Genetic M odulator of NMDAR Signaling to Govern Invasive Tumor Growth Graphical (2018) (0)
Exploratory analysis of multiprotein serum predictors at baseline of progression-free survival of ipilimumab or ipilimumab and nivolumab in the Checkmate-069 study. (2017) (0)
Immune Enhancement of Skin Carcinogenesis by CD4 (cid:2) T Cells (2003) (0)
Abstract 752: A CCR4 antagonist combined with protein-or DNA-based vaccines efficiently breaks tolerance and elicits CD8+T cells directed against self and viral associated tumor antigens (2011) (0)
Angiogenesis Fibronectin in Physiological and Tumor EIIIB Alternatively Spliced Segments of Direct Test of Potential Roles of EIIIA and (2004) (0)
Systematic identification of epigenetic alterations across human cancers therapeutic targets in cancer. (2017) (0)
Abstract LB-24: Molecular subtypes of pancreatic adenocarcinoma with different biological characteristics and therapeutical responses (2011) (0)
BACR/BMS Special Conference ‘‘Tumour Vasculature: New Targets & Therapies’’ 25th/28th June 2006, Cirencester, UK (2006) (0)
Cancer hallmarks intersect with neuroscience in the tumor microenvironment. (2023) (0)
Abstract LB-403: Recurrent fusion transcripts in breast cancer (2012) (0)
Initial evaluation of novel 99mTc radiolabeled peptides targeting the neovasculature in an endocrine pancreatic cancer model (2010) (0)
ID: 356 Distinct roles for cysteine cathepsins in multistage tumorigenesis (2006) (0)
The daunting complexity of cancer: understanding the battlefield is a step towards winning the war (2015) (0)
College of Medicine--The University of Arizona. Department of biochemistry. (1967) (0)
Procathepsin E is highly abundant but only partially active in Pancreatic Ductal Adenocarcinoma Tumors (2017) (0)
Abstract 1907: Multi-step microRNA control of pancreatic neuroendocrine tumors metastatic cascade (2016) (0)
Abstract B41: Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma (2022) (0)
The new determinants of the invasive growth hallmark of cancer (2013) (0)
Swiss Medical Weekly congratulates Jaco van Rheenen, recipient of the Dr Josef Steiner Cancer Research Foundation Award for 2017. (2017) (0)
Tumour cells mirror embryonic developmental programs to acquire invasive and metastatic capabilities (2019) (0)
Abstract 4391: CD20 as a target for therapy in solid tumors (2012) (0)
Exploring key genes and potential therapeutic and predictive targets between pyroptosis genes and adult extent of malignant glioma based on bioinformatics analysis (2022) (0)
Targeted Expression of Viral Genes to Pancreatic β Cells in Transgenic Mice (1989) (0)
Although tumor hypoxia increased after VEGF blockade in all three model systems , only 2 to 6 % of all CA 9 + cells were (2017) (0)
Abstract #LB-155: Recombinant Listeria monocytogenes expressing HPV16 E7 induces E7-specific CD8+ T cells in a novel mouse model of human cervical cancer (2009) (0)
The comparative genetics and genomics of cancer: of mice and men (2003) (0)
Abstracts of papers presented at the 1990 Meeting on Mouse Molecular Genetics, August 29-September 2, 1990 (1990) (0)
Failure of Tumor Immunity Resulting from Inaccessibility of Activated Lymphocytes to Solid Tumors (1998) (0)
14th Pezcoller Symposium: The Novel Dichotomy of Immune Interactions with Tumors 30 May–1 June 2002, Trento, Italy (2002) (0)
Distinct mTOR Pathway Activity in Neuroendocrine Tumors of the Pancreas and Small Intestine Revealed by Immunohistochemical Analysis (2010) (0)
Immunoelectron microscopical features of pancreatic B-cell tumours developed in transgenic mice and in rat islet cell tumour lines (1985) (0)
Abstract 1652: Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM models (2021) (0)
Dual Targeting of the Auto phagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit Graphical (2015) (0)
Abstracts of papers presented at the 1988 Meeting on Mouse Molecular Genetics, August 24-August 28, 1988 (1988) (0)
Abstract LB-301: Copper chelation therapy suppresses tumor growth by inhibiting mitochondrial ATP production in tumors. (2013) (0)
SV40 T antigen transgenic mice: cytotoxic T lymphocytes as a selective force in tumor progression. (1991) (0)
Perspectives on the Future of Angiogenesis Research (2008) (0)
Abstract B40: Co-targeting autophagy, macrophages and vasculature in glioma tumors triggers tumor immunity (2022) (0)
A personalised approach for anti-GITR-based immunotherapy in pre-clinical models of pancreatic ductal adenocarcinoma (2019) (0)

This paper list is powered by the following services:

Other Resources About Douglas Hanahan

en.wikipedia.org

What Schools Are Affiliated With Douglas Hanahan?

Douglas Hanahan is affiliated with the following schools: